Name: UMIN ID:
Unique ID issued by UMIN | UMIN000018777 |
---|---|
Receipt number | R000021562 |
Scientific Title | A randomized, double-blind, placebo-controlled, crossover study of the efficacy of omalizumab in patients with aspirin-exacerbated respiratory disease (AERD) |
Date of disclosure of the study information | 2015/08/24 |
Last modified on | 2019/08/26 16:43:42 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/08/23 21:12:43 | ||
2 | Update | 2015/08/24 18:05:24 | Recruitment status |
|
3 | Update | 2015/11/01 22:16:30 | Randomization unit |
|
4 | Update | 2017/02/22 10:33:35 | Name of primary person or sponsor Organization Category of Funding Organization |
|
5 | Update | 2017/02/22 10:35:09 | Recruitment status |
|
6 | Update | 2018/12/04 10:15:21 | Email Email1 |
|
7 | Update | 2019/08/26 16:37:23 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
8 | Update | 2019/08/26 16:40:00 | Number of participants that the trial has enrolled |
|
9 | Update | 2019/08/26 16:43:42 | Date of IRB Last follow-up date |